CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kilbey, A.
Right arrow Articles by Bartholomew, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kilbey, A.
Right arrow Articles by Bartholomew, C.
Cell Growth & Differentiation Vol. 10, 601-610, September 1999
© 1999 American Association for Cancer Research

Loss of Cell Cycle Control by Deregulation of Cyclin-dependent Kinase 2 Kinase Activity in Evi-1 Transformed Fibroblasts1

Anna Kilbey2, Victoria Stephens and Chris Bartholomew2,, 3

Cancer Research Campaign Beatson Laboratories, Beatson Institute for Cancer Research, Glasgow, Scotland

The Evi-1 transcriptional repressor protein has two distinct zinc finger DNA binding domains designated ZF1 and ZF2 and is implicated in the progression of human and murine leukemias, in which it is abnormally expressed. In this report, we show that Evi-1-expressing Rat1 fibroblasts are anchorage independent, have an abbreviated G1 phase of the cell cycle, and have a reduced requirement for serum mitogens for S-phase entry. These biological changes are accompanied by a moderately increased production of cell cycle-regulatory proteins cyclin A and cyclin-dependent kinase (Cdk) 2, a dramatic deregulation of Cdk2 kinase activity, and a corresponding increase in the levels of hyperphosphorylated retinoblastoma protein (pRb). We show that the elevated cyclin A-Cdk2 activity is due to the combination of increased accumulation and stabilization of cyclin A bound to a faster-migrating species of Cdk2 believed to be the active threonine 160 phosphorylated form and a substantial reduction in complexed p27. Cyclin E kinase activity is also elevated due to a reduction in p27. A significant reduction in total cellular p27 protein levels and a moderate reduction in p27 mRNA are observed, but no changes in Cdk regulatory kinases and phosphatases occur. The Evi-1 transcriptional repressor domain and the ZF1 DNA binding domain are required for both cell transformation and induction of Cdk2 catalytic activity. We propose that one consequence of Evi-1 expression is to repress the transcription of target genes, which may include p27, that deregulate the normal control of the G1 phase of the cell cycle, providing a cellular proliferative advantage that contributes to transformation in vitro and leukemogenesis in vivo.




This article has been cited by other articles:


Home page
J Biol ChemHome page
M. Wilson, V. Tsakraklides, M. Tran, Y.-Y. Xiao, Y. Zhang, and A. S. Perkins
EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements
J. Biol. Chem., June 24, 2016; 291(26): 13591 - 13607.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Dickstein, V. Senyuk, K. Premanand, L. Laricchia-Robbio, P. Xu, F. Cattaneo, R. Fazzina, and G. Nucifora
Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome
PNAS, May 25, 2010; 107(21): 9783 - 9788.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
B. Yatsula, S. Lin, A. J. Read, A. Poholek, K. Yates, D. Yue, P. Hui, and A. S. Perkins
Identification of Binding Sites of EVI1 in Mammalian Cells
J. Biol. Chem., September 2, 2005; 280(35): 30712 - 30722.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
L. C. Tu, T. Melendy, and T. A. Beerman
DNA damage responses triggered by a highly cytotoxic monofunctional DNA alkylator, hedamycin, a pluramycin antitumor antibiotic
Mol. Cancer Ther., May 1, 2004; 3(5): 577 - 586.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
S. Palmer, J.-P. Brouillet, A. Kilbey, R. Fulton, M. Walker, M. Crossley, and C. Bartholomew
Evi-1 Transforming and Repressor Activities Are Mediated by CtBP Co-repressor Proteins
J. Biol. Chem., July 13, 2001; 276(28): 25834 - 25840.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Solorzano, M. S. Rieber, and M. Rieber
Lower Cyclin H and Cyclin-dependent Kinase-activating Kinase Activity in Cell Cycle Arrest Induced by Lack of Adhesion to Substratum
Cancer Res., December 1, 2000; 60(24): 7114 - 7118.
[Abstract] [Full Text]


Home page
J Biol ChemHome page
S. Palmer, J.-P. Brouillet, A. Kilbey, R. Fulton, M. Walker, M. Crossley, and C. Bartholomew
Evi-1 Transforming and Repressor Activities Are Mediated by CtBP Co-repressor Proteins
J. Biol. Chem., July 13, 2001; 276(28): 25834 - 25840.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1999 by the American Association of Cancer Research.